JP2019527200A5 - - Google Patents

Download PDF

Info

Publication number
JP2019527200A5
JP2019527200A5 JP2018566552A JP2018566552A JP2019527200A5 JP 2019527200 A5 JP2019527200 A5 JP 2019527200A5 JP 2018566552 A JP2018566552 A JP 2018566552A JP 2018566552 A JP2018566552 A JP 2018566552A JP 2019527200 A5 JP2019527200 A5 JP 2019527200A5
Authority
JP
Japan
Prior art keywords
amino acid
polypeptide
scil
monomer subunit
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018566552A
Other languages
English (en)
Japanese (ja)
Other versions
JP7084881B2 (ja
JP2019527200A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/038747 external-priority patent/WO2018005226A2/en
Publication of JP2019527200A publication Critical patent/JP2019527200A/ja
Publication of JP2019527200A5 publication Critical patent/JP2019527200A5/ja
Application granted granted Critical
Publication of JP7084881B2 publication Critical patent/JP7084881B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018566552A 2016-06-22 2017-06-22 Il-10の免疫刺激特性および抗炎症特性を調節するための組成物および方法 Expired - Fee Related JP7084881B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662353478P 2016-06-22 2016-06-22
US62/353,478 2016-06-22
PCT/US2017/038747 WO2018005226A2 (en) 2016-06-22 2017-06-22 Compositions and methods for modulating il-10 immunostimulatory and anti-inflammatory properties

Publications (3)

Publication Number Publication Date
JP2019527200A JP2019527200A (ja) 2019-09-26
JP2019527200A5 true JP2019527200A5 (enExample) 2020-07-30
JP7084881B2 JP7084881B2 (ja) 2022-06-15

Family

ID=60674961

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018566552A Expired - Fee Related JP7084881B2 (ja) 2016-06-22 2017-06-22 Il-10の免疫刺激特性および抗炎症特性を調節するための組成物および方法

Country Status (6)

Country Link
US (2) US10335459B2 (enExample)
EP (1) EP3474884A4 (enExample)
JP (1) JP7084881B2 (enExample)
AU (2) AU2017291321B2 (enExample)
CA (1) CA3026393C (enExample)
WO (1) WO2018005226A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX354016B (es) 2010-09-15 2018-02-07 J Mrsny Randall Sistemas y metodos de suministro de agentes bioactivos mediante el uso de secuencias transportadoras derivadas de toxinas.
US11246915B2 (en) 2010-09-15 2022-02-15 Applied Molecular Transport Inc. Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
EP3139965B1 (en) 2014-05-07 2021-09-29 Applied Molecular Transport Inc. Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
AU2015364396B2 (en) 2014-12-19 2018-08-09 Alkermes, Inc. Single chain Fc fusion proteins
EP3474884A4 (en) 2016-06-22 2020-08-19 Alkermes, Inc. COMPOSITIONS AND METHODS FOR MODULATING THE IMMUNOSTIMULANT AND ANTI-INFLAMMATORY PROPERTIES OF IL-10
JP7404331B2 (ja) * 2018-03-23 2023-12-25 ガビッシュ-ガリラヤ バイオ アプリケーションズ リミテッド 膜結合型IL-10をコードする核酸分子及びそれを発現する遺伝子的にリプログラミングされたTreg
PT3650037T (pt) 2018-11-07 2022-06-27 Applied Molecular Transport Inc Construções de administração para transcitose e métodos relacionados
CN113811549A (zh) * 2019-02-21 2021-12-17 Xencor股份有限公司 非靶向和靶向性il-10 fc融合蛋白
CA3150859A1 (en) 2019-08-16 2021-02-25 Applied Molecular Transport Inc. Compositions, formulations, and interleukin production and purification
EP3795583A1 (en) * 2019-09-19 2021-03-24 Ecole Polytechnique Federale de Lausanne (EPFL) Il10/fc fusion proteins useful as enhancers of immunotherapies
CN112625137B (zh) * 2019-10-08 2021-10-08 北京东方百泰生物科技股份有限公司 一种人白细胞介素10-Fc融合蛋白及其医药用途
PT4065585T (pt) 2019-11-25 2025-09-30 Alkermes Inc Compostos macrocíclicos substituídos e métodos de tratamento relacionados
AU2021247185A1 (en) * 2020-04-03 2022-11-03 Baylor College Of Medicine TNFα signaling triggers tumor-promoting inflammation that can be targeted to therapy
KR20230009430A (ko) 2020-05-12 2023-01-17 리제너론 파아마슈티컬스, 인크. 신규 il10 효능제 및 그의 사용 방법
AU2021282361A1 (en) * 2020-05-28 2023-01-05 The Board Of Trustees Of The Leland Stanford Junior University Engineered interleukin-10 polypeptides and uses thereof
US11760747B2 (en) 2020-12-21 2023-09-19 Alkermes, Inc. Substituted piperidino compounds and related methods of treatment
WO2024094755A1 (en) * 2022-11-02 2024-05-10 Synerkine Pharma B.V. Engineered immunocytokines, fusion polypeptides, and il10 polypeptides
CN118221829A (zh) * 2022-12-21 2024-06-21 广东菲鹏制药股份有限公司 一种il-10单体融合蛋白
WO2024144336A1 (ko) * 2022-12-30 2024-07-04 주식회사 프로젠 신규 이중 특이성 융합단백질 및 그의 용도
KR20260034078A (ko) * 2023-06-02 2026-03-10 신테카인, 인크. 융합된 il10 폴리펩티드
WO2025247362A1 (zh) * 2024-05-31 2025-12-04 江苏先声生物制药有限公司 抗cdh17抗体、缀合物及其应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10399023I2 (de) 1989-09-12 2006-11-23 Ahp Mfg B V TFN-bindende Proteine
JP2002530066A (ja) 1998-11-19 2002-09-17 スミスクライン・ビーチャム・コーポレイション Rhammアンタゴニスト抗体
US6428985B1 (en) * 1998-12-02 2002-08-06 The Regents Of The University Of Michigan Immunosuppressive structural definition of IL-10
AU782496B2 (en) 1999-07-13 2005-08-04 Bolder Biotechnology, Inc. Immunoglobulin fusion proteins
AU2001231532A1 (en) * 2000-02-11 2001-08-20 Maxygen Aps Improved interleukin 10
AU2003280315A1 (en) * 2002-11-14 2004-06-03 Maxygen, Inc. Conjugates of interleukin-10 and polymers
PT1624891E (pt) 2003-05-06 2010-01-05 Syntonix Pharmaceuticals Inc Proteínas quiméricas de factor de coagulação-fc destinadas ao tratamento da hemofilia
US7696322B2 (en) 2003-07-28 2010-04-13 Catalent Pharma Solutions, Inc. Fusion antibodies
US20150071948A1 (en) 2003-09-26 2015-03-12 Gregory Alan Lazar Novel immunoglobulin variants
WO2008140595A2 (en) 2006-12-01 2008-11-20 President And Fellows Of Harvard College Synthetic trivalent haptens, complexes thereof, and uses therefor
JP2013514795A (ja) 2009-12-22 2013-05-02 ノバルティス アーゲー 治療における使用のための四価cd47抗体定常領域融合タンパク質
SG181952A1 (en) 2009-12-29 2012-07-30 Emergent Product Dev Seattle Heterodimer binding proteins and uses thereof
AR080993A1 (es) 2010-04-02 2012-05-30 Hanmi Holdings Co Ltd Formulacion de accion prolongada de interferon beta donde se usa un fragmento de inmunoglobulina
WO2011140595A2 (en) 2010-05-10 2011-11-17 4G Vaccines Pty Ltd Immunostimulatory and vaccine compositions
CN101962413B (zh) * 2010-09-21 2013-03-13 中国科学技术大学 具有透皮能力和白细胞介素-10活性的融合蛋白及其编码基因与应用
US8883134B2 (en) 2010-10-20 2014-11-11 Handok Pharmaceuticals, Inc. Human interleukin-1 receptor antagonist—hybrid Fc fusion protein
EP2457579A1 (en) 2010-11-26 2012-05-30 Technische Universität Dresden Covalently linked interleukin -10
TWI588156B (zh) 2011-03-28 2017-06-21 賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
EA201892619A1 (ru) * 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
ES2758884T3 (es) 2011-06-24 2020-05-06 Stephen D Gillies Proteínas de fusión de inmunoglobulina a través de cadena ligera y métodos de uso de ellas
PH12013502531A1 (en) 2011-08-23 2014-01-20 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
US9062120B2 (en) 2012-05-02 2015-06-23 Janssen Biotech, Inc. Binding proteins having tethered light chains
LT3401402T (lt) * 2012-06-08 2020-12-28 Alkermes Pharma Ireland Limited Ligandai, modifikuoti cirkuliarinės permutacijos pagalba, kaip agonistai ir antagonistai
AU2013293092A1 (en) 2012-07-23 2015-02-26 Zymeworks Inc. Immunoglobulin constructs comprising selective pairing of the light and heavy chains
PE20150645A1 (es) * 2012-08-08 2015-05-11 Roche Glycart Ag Proteinas de fusion de interleuquina 10 y usos de las mismas
EP2970484B2 (en) 2013-03-15 2022-09-21 Amgen Inc. Heterodimeric bispecific antibodies
US20160068583A1 (en) 2013-04-24 2016-03-10 Armo Biosciences, Inc. Interleukin-10 Compositions and Uses Thereof
MX2016001165A (es) 2013-07-31 2016-06-29 Amgen Inc Estabilizacion de polipeptidos que contienen fragmentos cristalizables.
RU2016135788A (ru) 2014-02-06 2018-03-07 Ф.Хоффманн-Ля Рош Аг Иммуноконъюгаты интерлейкина 10
CN104403004B (zh) 2014-11-24 2017-10-13 苏州丁孚靶点生物技术有限公司 抗体‑干扰素异二聚体的制备和用途
AU2015364396B2 (en) 2014-12-19 2018-08-09 Alkermes, Inc. Single chain Fc fusion proteins
CA3016563A1 (en) 2016-03-21 2017-09-28 Elstar Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
EP3474884A4 (en) 2016-06-22 2020-08-19 Alkermes, Inc. COMPOSITIONS AND METHODS FOR MODULATING THE IMMUNOSTIMULANT AND ANTI-INFLAMMATORY PROPERTIES OF IL-10

Similar Documents

Publication Publication Date Title
JP2019527200A5 (enExample)
JP2005120106A5 (enExample)
JP2009524429A5 (enExample)
JP2017512063A5 (enExample)
JP2016000731A5 (enExample)
JP2018510622A5 (enExample)
JP2015525217A5 (enExample)
JP2013520426A5 (enExample)
JP2010519252A5 (enExample)
IL294059A (en) Mutant rsv f protein and its use
JP2019033754A5 (enExample)
JP2014224126A5 (enExample)
HRP20240640T1 (hr) Kimerni proteini faktora viii i njihova upotreba
HRP20240135T1 (hr) Fgf21 mutanti i njihove upotrebe
JP2014510518A5 (enExample)
HRP20221531T1 (hr) Pripravci faktora viii i postupci dobivanja i korištenja istih
JP2019163253A5 (enExample)
JP2014509851A5 (enExample)
JP2019522465A5 (enExample)
JP2011501951A5 (enExample)
JP2017536098A5 (enExample)
JP2012532601A5 (enExample)
JP2018504911A5 (enExample)
JP2017509335A5 (enExample)
JP2014525439A5 (enExample)